Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)
China · Delayed Price · Currency is CNY 29.82
-0.94 (-3.06%)
Sep 10, 2026, 3:04 PM CST
SHE:300584 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 3,691 | 6,026 | 2,419 | 2,794 | 3,864 | 2,400 | |
Market Cap Growth | -60.50% | 149.11% | -13.40% | -27.70% | 61.00% | -2.53% |
Enterprise Value | 3,993 | 6,278 | 2,671 | 2,943 | 3,897 | 2,479 |
Last Close Price | 30.76 | 50.10 | 20.05 | 23.08 | 31.92 | 19.68 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 82.09 | 143.29 | 60.15 | 76.93 | 119.08 | 8.40 |
Forward PE | - | 26.20 | 26.20 | 26.20 | 26.20 | 26.20 |
PS Ratio | 5.08 | 8.98 | 4.80 | 5.40 | 7.34 | 4.15 |
PB Ratio | 3.29 | 5.48 | 2.33 | 2.83 | 4.07 | 2.53 |
P/TBV Ratio | 3.83 | 6.45 | 2.74 | 3.25 | 4.73 | 2.90 |
P/FCF Ratio | - | 390.08 | - | - | - | - |
P/OCF Ratio | 318.94 | 77.17 | 40.35 | 116.73 | - | 40.04 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.50 | 9.36 | 5.30 | 5.68 | 7.40 | 4.29 |
EV/EBITDA Ratio | 23.20 | 43.01 | 25.36 | 29.58 | 47.13 | 37.32 |
EV/EBIT Ratio | 39.78 | 76.50 | 50.98 | 64.05 | 112.54 | 84.27 |
EV/FCF Ratio | - | 406.33 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.25 | 0.26 | 0.30 | 0.27 | 0.19 | 0.19 |
Debt / EBITDA Ratio | 1.60 | 1.96 | 2.99 | 2.72 | 2.15 | 2.71 |
Debt / FCF Ratio | - | 18.56 | - | - | - | - |
Net Debt / Equity Ratio | 0.23 | 0.20 | 0.26 | 0.23 | 0.09 | 0.07 |
Net Debt / EBITDA Ratio | 1.47 | 1.51 | 2.55 | 2.25 | 1.00 | 0.97 |
Net Debt / FCF Ratio | -8.76 | 14.28 | -14.96 | -1.29 | -0.37 | -1.88 |
Asset Turnover | 0.48 | 0.45 | 0.35 | 0.38 | 0.41 | 0.52 |
Inventory Turnover | 2.03 | 1.53 | 1.11 | 1.39 | 2.24 | 1.74 |
Quick Ratio | 0.87 | 0.78 | 0.74 | 0.64 | 0.96 | 0.79 |
Current Ratio | 1.19 | 1.04 | 1.07 | 0.94 | 1.19 | 1.00 |
Return on Equity (ROE) | 4.11% | 3.81% | 3.96% | 3.75% | 3.38% | 35.00% |
Return on Assets (ROA) | 4.25% | 3.42% | 2.28% | 2.13% | 1.67% | 1.67% |
Return on Invested Capital (ROIC) | 6.23% | 5.38% | 4.07% | 3.94% | 3.38% | 2.90% |
Return on Capital Employed (ROCE) | 8.60% | 7.10% | 4.60% | 4.60% | 3.50% | 2.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.22% | 0.70% | 1.66% | 1.30% | 0.84% | 11.91% |
FCF Yield | -0.79% | 0.26% | -0.74% | -6.20% | -5.82% | -1.44% |
Dividend Yield | 0.32% | 0.20% | 0.50% | 0.22% | - | 1.27% |
Payout Ratio | 42.56% | 46.38% | 34.44% | 17.80% | 109.40% | 7.70% |
Buyback Yield / Dilution | - | 0.02% | -0.01% | -0.01% | -0.00% | -0.01% |
Total Shareholder Return | 0.32% | 0.22% | 0.49% | 0.21% | -0.00% | 1.26% |